TY - JOUR T1 - Tumor Boost Using External Beam Radiation in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy: Outcome From a Multicenter Retrospective Study (Korean Radiation Oncology Group 1419) JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 371 LP - 378 DO - 10.1097/IGC.0000000000001155 VL - 28 IS - 2 AU - Haeyoung Kim AU - Young Seok Kim AU - Ji Hyeon Joo AU - Keun-Yong Eom AU - Won Park AU - Jin Hee Kim AU - Jong Hoon Lee AU - Yeon Sil Kim AU - Seok Ho Lee AU - Kijung Ahn AU - Yong Bae Kim AU - Me-Yeon Lee AU - Sei Kyung Chang Y1 - 2018/02/01 UR - http://ijgc.bmj.com/content/28/2/371.abstract N2 - Purpose We conducted this study to evaluate the outcomes of external-beam radiotherapy tumor boost (EBRT-B) in cervical cancer patients who could not receive intracavitary brachytherapy.Methods A total of 11 hospitals provided the data of patients who received EBRT-B during the period from January 2005 through October 2012.Results A total of 75 patients were included. The median radiotherapy dose was 46 Gy (range, 40–54 Gy) for whole pelvis and 24 Gy (range, 9–35 Gy) for EBRT-B. Initial tumor responses assessed at 2 to 6 months after radiotherapy were as follows: 46 with complete response, 22 with partial response, 2 with stable disease, and 3 with progressive disease. After a median follow-up time of 33 months, 30 patients (40.0%) showed disease progression including 21 (28.0%) with local progression. The 5-year local failure-free survival rate was 70.0%. Achieving complete response at the first follow-up visit and an overall treatment time of 53 days or less were significantly related to favorable local failure-free survival. The rate of grade 3 or higher toxicity was 2.6%.Conclusions Approximately 70% of patients had local tumor control after curative radiotherapy using EBRT-B. Early tumor response and overall treatment time of 53 days or less were closely associated with favorable local control. ER -